Autoimmunity has been implicated in the pathogenesis of ulcerative colitis (UC). Several studies have shown amplified immunoglobulin Gi (IgG1) antibody response in UC; however the immunoreactive antigen(s) is unknown. To study this antigen(s), mucosal colonic extract was prepared by sonication, ultracentrifugation followed by ion exchange chromatography in fast protein liquid chromatography. The fraction (enriched colonic peptide), that was most reactive to a novel monoclonal antibody, 7E,2H12
(IgM isotype), was isolated and used to examine the immunoreactivity against the patients' serum samples. Two hundred and thirteen coded samples from 111 patients with UC (symptomatic and untreated (63), symptomatic and treated (26), remission (22) Although the cause of ulcerative colitis (UC) is unknown, autoimmunity plays an important part in its pathogenesis.' Serum autoantibodies to colonic epithelial cells have been identified in up to 60% of patients with UC2-4 and occur at a lower frequency in their relatives.5 The autoantibodies have been described both against colonic goblet cells as well as absorbtive epithelial cells. In UC, an amplified immunoglobulin G1 (IgGI) antibody response in the circulation6 and in situ7 have been reported. In the second group there was also deposition of IgGl together with activated early (Cl q, C4c, C3b) and late (terminal complement complex) components of the complement cascade, on the apical face of the colonic epithelium in patients with active UC but not in patients with Crohn's colitis. 7 (6) , giardia (6) , amoebiasis (5) , cryptosporidia (3) , Cl difficile (2). agarose (2 ml) at a concentration of 1 mg/ml in coupling buffer (0-1 M NaHCO3, pH 8 5 (1) The microtitre plate was coated with purified serum IgGl from each of the 10 subjects in a concentration of 1 ,ug/well in triplicate/100 RI1 of coating buffer (pH 9 6) and left at 4°C for overnight. The next day, after washing three times in PBS/TWEEN 20 (0-1%), the plate is blocked with 0.25 /% bovine serum albumin in PBS. After this, sequential steps included incubation with FPLC purified 0-48 M NaCl mucosal extract (enriched colonic peptide) (2 ,ug/well), for one hour at 370C, washed with PBSfiTWEEN 20, and then incubated with 7E12H12 1gM (1 ,ug/well) for one hour at 37°C, followed by alkaline-phosphatase conjugated antimouse IgM (Zymed, 1:15 000, one hour at room temperature). Substrate buffer was added as described above and optical density was measured at 405 nm in the ELISA reader. The binding of IgGl to the plate was confirmed with alkaline-phosphatase labelled antihuman IgG run in parallel. Antigen control included similarly extracted small intestinal protein(s) in place of 0A48 M NaCl colon extract and an unrelated murine IgM monoclonal antibody (MOPC-104E) was used as control in place of 7E12H12 IgM.
(2) The microtitre plate was coated with purified 7E12H12 1gM to capture the antigen. The plate was coated with 7E12H12 1gM (0 5 ,ug/well) followed by 0-48 M NaCl colon extract and then with purified human serum IgGI. Detection system in this case was alkaline phosphatase labelled goat antihuman IgG. do not change the 7E12H12 monoclonal antibody reactivity; whereas trypsin digestion destroys the activity. Figure 1 shows the ELISA data of IgGI antibody responses with all 213 subjects. The highest background value of this ELISA with a non-inflammatory bowel disease subject was an optical density of 0d125 with a normal serum. The mean (SEM) value for all normal subjects was 0 040 (0 008). Eighty eight serum samples from the total 111 (79%) UC patients produced an optical density higher than 0-125. Only six of 47 CD serum samples (12%) had an optical density value higher than 0G125. Table II summarises the results in all patients with different clinical activities and their statistical analysis. The mean (SEM) value for UC group with symptomatic disease without any treatment was 0 199 (0-009), symptomatic UC treated with corticosteroids was 0-204 (0 024); UC in remission was 0d160 (0-018). The mean value for CD group with active disease was 0'077 (0-012) and for CD patients in remission it was 0-067 (0-014). The mean value for symptomatic diarrhoeal patients was 0-028 (0 006) and for systemic lupus erythematosus patients the mean optical density value was 0-009 (0 005). The difference between the mean value for each of the UC subgroups (treated or untreated, symptomatic or in remission) is highly significant (p=<0001 to 0-0001) against each non-UC group (Table II) . There was no difference in IgG2 and the IgG3 responses. IgG4 response was not examined.
Results
Table II also shows the total IgG antibody response in the UC group, particularly patients with symptomatic colitis without being treated, the mean (SEM) optical density was the highest at 0-190 (0-014) followed by symptomatic patients who were treated. The background optical density for total IgG with normal subjects and diarrhoeal patients was 0 073 and 0-079 respectively; patients with active CD and UC in remission had mean optical density values 0-096 and 0 108 respectively. Statistical analysis of total Igs responses showed that only symptomatic patients with UC treated or untreated had significantly higher (p=<0 05 to <0.001) optical density than each of the non-UC group. The optical density value in patients with UC in remission, however, was not significantly different than any of the non-IBD group.
The IgGl responses against the E coli extract was measured with 20 UC, 10 CD, and 10 normal serum samples. The mean (SEM) optical density values for UC, CD, and normal subjects were 0 161 (0-018), 0-212 (0-055), and 0-238 (0 039) respectively. The differences among these values were not statistically significant. The total IgG response in UC (0-487 (0 064)) was also similar to normal subjects (0-479 (0-083)).
Figure 2 and Table III IgM against the antigen was tested; (B) the antigen was first captured by coating the plate with 7E12H12 IgM and the reactivity was examined using serum IgGI. A highly significant (p<O0OOO1) reactivity was evident in UC in both (A) and (B).
antibodies against the same peptide. Such reactivity was not seen with CD-IgG1 MOPC-1 04E, and when small intestinal mucosal extract was used in place of enriched colonic peptide (Fig 2 and 
